CT of the liver and spleen with EOE-13: review of 225 examinations.
EOE-13 is an experimental liver-spleen-specific computed tomographic (CT) contrast agent developed at the National Institutes of Health. Experience with this agent in 225 clinical examinations is described. On average, use of EOE-13 increases the attenuation of normal liver by 32.5 H and that of normal spleen by 52.3 H. Tumors in these organs increase only 2.6 H, making them more easily detectable. Most of the iodine in EOE-13 appears to clear from the liver and spleen by 24 hr after injection. No deaths or permanent morbidity have been observed. The complication rate is 3.6%. EOE-13 is valuable for the detection of hepatic and splenic tumors.
D000328:Adult; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D004998:Ethiodized Oil / Q000009:adverse effects; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007263:Infusions, Parenteral; D008099:Liver / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000473:pathology; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D008198:Lymph Nodes / Q000187:drug effects / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009127:Muscle Rigidity / Q000139:chemically induced; D013154:Spleen / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000473:pathology; D013160:Splenic Neoplasms / Q000000981:diagnostic imaging; D014057:Tomography, X-Ray Computed / Q000379:methods*
D004998:Ethiodized Oil